【摘要】 目的 探讨肺表面活性物质(PS)在治疗新生儿肺透明膜病(HMD)Ⅱ级的疗效。方法 对60例经X线胸片检查为HMDⅡ级的患儿。30例6小时内应用肺表面活性物质;30例无应用肺表面活性物质,通过用药后20小时(或约生后24小时)X线胸片的诊断与上呼吸机时间、并发症的比较分析,评价肺表面活性物质治疗肺透明膜病的疗效。结果 两组病例在生后24小时的X线胸片,平均上呼吸机时间,住院天数、死亡率,有显著性差异,P<0.05。并发症方面,肺炎发生率显著性差异,P<0.05。结论 PS在治疗HMD中可以明显改善肺透明膜病的转归,减少并发症,降低死亡率。更多还原

【Abstract】 Objective To explore effect of pulmonary surfactant replacement therapy in 2nd degree hyaline membrane disease. Methods Sixty premature infants is diagnosed as 2nd degree hyaline membrane disease by X-ray. Pulmonary surfactant was admitted to thirty premature with six hours of age, the others didn’t get PS and worked as control. Analyse X-ray result and time of respirator utilization and complications after twenty hours. Results There were significance difference(P<0.05) X-ray at 24 hrs of age, average time of respirator utilization, days of hospital stay, death rate and pneumonia incidence. Conclusion PS can improve HMD pathological changes, reduce complication and death rate.更多还原